Abstract:Importance The recombinant zoster vaccine (RZV) is currently recommended for immunocompetent adults aged 50 years or older and immunocompromised adults aged 19 years or older and is effective in preventing herpes zoster ophthalmicus (HZO). However, questions about the safety of RZV in patients with a history of HZO remain. Objective To evaluate whether there is an increased risk of HZO recurrence after RZV in patients with a history of HZO. Design, Setting, and Participants This retrospective cohort study used medical and outpatient pharmacy claims data for commercial and Medicare Advantage enrollees from the Optum Labs Data Warehouse. Patients with incident HZO from January 1, 2010, to December 31, 2021, were identified; the study period ended on March 31, 2022. The vaccinated group consisted of patients with at least 1 dose of RZV more than 90 days following the initial HZO diagnosis. The unvaccinated group consisted of patients without any record of RZV in the study period. Vaccinated and unvaccinated patients were matched using exact k:1 matching without replacement. Exposure Recombinant zoster vaccination. Main Outcomes and Measures The main outcome was the number of HZO recurrences with and without RZV exposure. Results A total of 16 408 patients were included in the matched analysis, of whom 12 762 were unvaccinated (7806 [61.2%] female; mean [SD] age at diagnosis, 68.8 [10.3] years) and 3646 were vaccinated (2268 [62.2%] female; mean [SD] age at diagnosis, 67.4 [9.8] years). Within the primary risk period of 56 days after the index date (ie, the start of follow-up for the outcome), the incidence of HZO recurrence after any RZV exposure was 37.7 per 1000 person-years compared with 26.2 per 1000 person-years in the unexposed group. After controlling for race and ethnicity, inpatient stays, emergency department visits, concomitant vaccines, and eye care practitioner visits, the association between vaccination status and HZO exacerbation in the primary risk period had an adjusted hazard ratio for any RZV exposure of 1.64 (95% CI, 1.01-2.67; P = .04). Conclusions and Relevance In this study, RZV exposure was associated with a higher likelihood of HZO recurrence in patients with a history of HZO compared with no RZV exposure. These findings support consideration that patients with a history of HZO may benefit from monitoring after receiving RZV in case of HZO recurrence.

Long‐term risk of herpes zoster following COVID‐19: A retrospective cohort study of 2 442 686 patients

A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination

The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX

Risk of herpes zoster in adults with SARS-CoV-2 infection in Spain: a population-based, retrospective cohort study

The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review

The Risk of Herpes Zoster in Women with Polycystic Ovary Syndrome: A Retrospective Population-Based Study

Assessing herpes zoster vaccine efficacy in patients with diabetes: A community‐based cohort study

Exploring the association between chronic prostatitis and the risk of herpes zoster in a cohort study in Taiwan

Herpes Zoster Ophthalmicus Clinical Presentation and Risk Factors for Lesion Recovery

Herpes Zoster Risk After Total Knee Replacement: a multicenter, propensity-score-matched cohort study in the United States

Herpes Zoster Reactivation After mRNA and Adenovirus-Vectored Coronavirus Disease 2019 Vaccination: Analysis of National Health Insurance Database

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2

Risk Factors for the Development of Ocular Complications in Herpes Zoster Ophthalmicus and Zoster Vaccine Utilization in a Large, Urban Health System

Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination

Association between a History of herpes zoster and the risk of Sjögrens syndrome: a nationwide, population-based, case-control study

Risk of cytomegalovirus diseases among coronavirus disease survivors: A retrospective cohort study

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study

Risk of dementia following herpes zoster infection among patients undertreatment versus those not: A systematic review and meta-analysis

Lifetime Risk of Herpes Zoster in the Population of Beijing, China

The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine

The risk of herpes zoster is positively associated with obesity, especially morbid obesity